Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2174 - Clinical factors associated with mutation burden in non-small cell lung cancer


11 Sep 2017


Poster display session


Translational Research;  Thoracic Malignancies


Akira Ono


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


A. Ono1, M. Serizawa2, K. Omae3, M. Isaka4, H. Kojima4, S. Takahashi4, K. Nakashima1, S. Omori1, K. Wakuda1, H. Kenmotsu1, T. Naito1, H. Murakami1, K. Urakami2, Y. Ohde4, T. Nakajima5, M. Kusuhara2, K. Yamaguchi6, T. Takahashi1

Author affiliations

  • 1 Thoracic Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Research Institute, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 3 Clinical Research Promotion Unit, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 4 Thoracic Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 5 Diagnostic Pathology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 6 Hospital And Research Institute, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP


Abstract 2174


PD-L1 expression is associated with clinical benefit from anti-PD1/anti-PD-L1 therapies in advanced NSCLC. However, additional biomarkers are needed to predict which patients will benefit most. The aim of this study is to correlate specific genomic alterations with immunological biomarkers in a cohort of NSCLC.


Patients diagnosed with NSCLC from 2000 to 2005 were retrospectively reviewed. Genetic mutations and copy number of selected genes were determined by Sanger and FISH. Immunophenotype was defined by PD-L1, HLA-1 and TILs CD8+ immunostaining and scored as follows: PD-L1 positivity ≥ 5% on membrane tumor cells; HLA-1 intensity: 0+,1+,2+; TILs CD8+ score: low or high infiltration. Statistical analysis using Chi-square test and logistic regression were performed.


From 150 patients: 87% males; stage: 90% I-II, 10% III-IV; histology: 42% adenocarcinoma (ADC), 44% squamous (SCC), 14% sarcomatoid carcinoma (SaC). Genomic alterations according to histologic subtype are summarized in Table. PD-L1 was positive in 47% of tumors (49% of ADC, 43% of SCC, 58% of SaC), and correlated with TILs CD8 + (p


MET and STK11 alterations were correlated with differential expression of tumor PD-L1. STK11 mutant tumors were more likely to have an immunosupressive phenotype. Tumors harbouring specific genomic alterations might be enriched for distinct immunophenotypes which might contribute to rational use of immunotherapies.

Clinical trial identification

Legal entity responsible for the study

IDIBELL-Institut Català d'Oncologia




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.